Publications
-
Antibiotics. Targeting DnaN for tuberculosis therapy using novel...
Published: 05/17/2019
The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy. Despite the subsequent development of a curative regimen for this disease, tuberculosis remains a worldwide problem, and the...
-
Cathepsin K Contributes to Cavitation and Collagen Turnover in...
Published: 05/17/2019
Cavitation in tuberculosis enables highly efficient person-to-person aerosol transmission. We performed transcriptomics in the rabbit cavitary tuberculosis model. Among 17 318 transcripts, we identified 22 upregulated proteases....
-
Clofazimine Contributes Sustained Antimicrobial Activity after...
Published: 05/17/2019
Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens. Clofazimine accumulates to high levels in...
-
Clofazimine has delayed antimicrobial activity against...
Published: 05/17/2019
Objectives
The anti-leprosy drug clofazimine has been shown to have antimicrobial activity against Mycobacterium tuberculosis and has been associated with treatment-shortening activity in both clinical and...
-
Non-classical transpeptidases yield insight into new...
Published: 05/17/2019
Bacterial survival requires an intact peptidoglycan layer, a three-dimensional exoskeleton that encapsulates the cytoplasmic membrane. Historically, the final steps of peptidoglycan synthesis are known to be carried out...
-
In vitro and in vivo activity of biapenem against...
Published: 05/17/2019
Background: Biapenem, a carbapenem antibiotic, has been shown to have synergistic bactericidal anti-TB activity when combined with rifampicin both in vitro and in the mouse model of TB chemotherapy. We hypothesized...
-
Impact of Clofazimine Dosing on Treatment Shortening of the...
Published: 05/17/2019
The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course regimen for multidrug-resistant tuberculosis. It also enables significant treatment shortening when added to the first-line regimen...
-
Shorter-course treatment for Mycobacterium ulcerans disease with...
Published: 05/17/2019
Starting in 2004, the standard regimen for treatment of Buruli ulcer (BU) recommended by the World Health Organization has been daily treatment for eight weeks with rifampin (RIF) and streptomycin. Based on recent clinical trials,...
-
In Vitro Activity of the New β-Lactamase Inhibitors Relebactam...
Published: 05/17/2019
Pulmonary disease due to infection with Mycobacterium abscessus complex (MABC) is notoriously difficult to treat, in large part due to the intrinsic resistance of MABC strains to most antibiotics, including...
-
Activity of a Long-Acting Injectable Bedaquiline Formulation in a...
Published: 05/17/2019
The potent antituberculosis activity and long half-life of bedaquiline make it an attractive candidate for use in long-acting/extended-release formulations for the treatment of latent tuberculosis infection (LTBI). Our objective...
- 1 2 3 > Last ›
